BLACK DIAMOND THERAPEUTICS, INC. Comprehensive Income
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Comprehensive Income of -$9.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-05
- BLACK DIAMOND THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$9.94M.
- BLACK DIAMOND THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$9.17M, a 116.24% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$15.16M.
- BLACK DIAMOND THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$8.33M.
- BLACK DIAMOND THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was $22.44M.
- BLACK DIAMOND THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$69.63M.
- BLACK DIAMOND THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$80.64M.
- BLACK DIAMOND THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$92.58M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$9.94M 10-Q · filed 2026-08-05 | -$19.11M 10-Q · filed 2026-08-05 | -$34.27M derived: sum of 3 quarters · filed 2026-08-05 | -$42.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$9.17M 10-Q · filed 2026-05-07 | -$24.33M derived: sum of 2 quarters · filed 2026-05-07 | -$32.66M derived: sum of 3 quarters · filed 2026-05-07 | -$43.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$15.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$23.49M derived: sum of 2 quarters · filed 2026-03-16 | -$34.05M derived: sum of 3 quarters · filed 2026-08-05 | $22.44M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$8.33M 10-Q · filed 2025-11-06 | -$18.90M derived: sum of 2 quarters · filed 2026-08-05 | $37.60M 10-Q · filed 2025-11-06 | $21.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$10.57M 10-Q · filed 2026-08-05 | $45.93M 10-Q · filed 2026-08-05 | $29.86M derived: sum of 3 quarters · filed 2026-08-05 | $14.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $56.50M 10-Q · filed 2026-05-07 | $40.43M derived: sum of 2 quarters · filed 2026-05-07 | $25.10M derived: sum of 3 quarters · filed 2026-05-07 | $5.17M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$16.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$31.40M derived: sum of 2 quarters · filed 2026-03-16 | -$51.33M derived: sum of 3 quarters · filed 2026-03-16 | -$69.63M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$15.34M 10-Q · filed 2025-11-06 | -$35.26M derived: sum of 2 quarters · filed 2025-11-06 | -$53.56M 10-Q · filed 2025-11-06 | -$72.63M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$19.93M 10-Q · filed 2025-08-07 | -$38.22M 10-Q · filed 2025-08-07 | -$57.29M derived: sum of 3 quarters · filed 2025-08-07 | -$80.00M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$18.29M 10-Q · filed 2025-05-12 | -$37.36M derived: sum of 2 quarters · filed 2025-05-12 | -$60.07M derived: sum of 3 quarters · filed 2025-05-12 | -$78.71M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$19.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$41.78M derived: sum of 2 quarters · filed 2025-03-06 | -$60.42M derived: sum of 3 quarters · filed 2025-03-06 | -$80.64M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$22.71M 10-Q · filed 2024-11-05 | -$41.35M derived: sum of 2 quarters · filed 2024-11-05 | -$61.57M 10-Q · filed 2024-11-05 | -$81.99M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$18.64M 10-Q · filed 2024-08-06 | -$38.86M 10-Q · filed 2024-08-06 | -$59.28M derived: sum of 3 quarters · filed 2024-08-06 | -$81.13M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$20.23M 10-Q · filed 2024-05-09 | -$40.64M derived: sum of 2 quarters · filed 2024-05-09 | -$62.50M derived: sum of 3 quarters · filed 2024-05-09 | -$85.94M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$20.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$42.27M derived: sum of 2 quarters · filed 2024-03-12 | -$65.71M derived: sum of 3 quarters · filed 2024-03-12 | -$92.58M 10-K · filed 2024-03-12 |
| 2022-09-30 | -$21.86M 10-Q · filed 2023-11-06 | -$45.30M derived: sum of 2 quarters · filed 2023-11-06 | -$72.17M 10-Q · filed 2023-11-06 | -$98.59M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$23.44M 10-Q · filed 2023-08-11 | -$50.31M 10-Q · filed 2023-08-11 | -$76.73M derived: sum of 3 quarters · filed 2023-08-11 | -$111.88M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$26.87M 10-Q · filed 2023-05-09 | -$53.29M derived: sum of 2 quarters · filed 2023-05-09 | -$88.44M derived: sum of 3 quarters · filed 2023-05-09 | -$122.91M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$26.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$61.57M derived: sum of 2 quarters · filed 2023-03-09 | -$96.04M derived: sum of 3 quarters · filed 2023-03-09 | -$126.62M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$35.15M 10-Q · filed 2022-11-08 | -$69.62M derived: sum of 2 quarters · filed 2022-11-08 | -$100.20M 10-Q · filed 2022-11-08 | -$123.09M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$34.48M 10-Q · filed 2022-08-09 | -$65.06M 10-Q · filed 2022-08-09 | -$87.94M derived: sum of 3 quarters · filed 2022-08-09 | -$105.99M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$30.58M 10-Q · filed 2022-05-11 | -$53.47M derived: sum of 2 quarters · filed 2022-05-11 | -$71.52M derived: sum of 3 quarters · filed 2022-05-11 | -$85.08M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | -$22.89M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$40.94M derived: sum of 2 quarters · filed 2022-03-17 | -$54.49M derived: sum of 3 quarters · filed 2022-03-17 | -$66.64M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$18.05M 10-Q · filed 2021-11-08 | -$31.61M derived: sum of 2 quarters · filed 2021-11-08 | -$43.75M 10-Q · filed 2021-11-08 | -$53.63M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | -$13.56M 10-Q · filed 2021-08-12 | -$25.70M 10-Q · filed 2021-08-12 | -$35.58M derived: sum of 3 quarters · filed 2021-08-12 | -$44.85M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$12.14M 10-Q · filed 2021-05-07 | -$22.02M derived: sum of 2 quarters · filed 2021-05-07 | -$31.29M derived: sum of 3 quarters · filed 2021-05-07 | -$43.58M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | -$9.88M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$19.14M derived: sum of 2 quarters · filed 2021-03-25 | -$31.43M derived: sum of 3 quarters · filed 2021-03-25 | -$35.26M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$9.27M 10-Q · filed 2020-11-10 | -$21.55M derived: sum of 2 quarters · filed 2020-11-10 | -$25.38M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$12.29M 10-Q · filed 2020-08-11 | -$16.11M 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |